Valneva (VALN)
(Delayed Data from NSDQ)
$7.76 USD
+0.11 (1.44%)
Updated Aug 23, 2024 11:05 AM ET
After-Market: $7.68 -0.08 (-1.03%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Valneva SE Sponsored ADR [VALN]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Additional Grant From CEPI to Fund Broader Access to Ixchiq in Low- and Middle-Income Countries
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Chikungunya Vaccine Ixchiq Receives Approval From European Commission
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Publication of Findings From Phase 2 Trials of VLA15 in Adults
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Further Positive Phase 3 Data in Adolescents Treated with Ixchiq
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
1Q24 Results; Phase 1 Zika Virus Vaccine Data Expected in 1H25; VALOR Data Still Expected YE25
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Clinical Re-entry of Zika Virus Vaccine Candidate VLA1601
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
FY23 Results; Updated FY24 Guidance; Ixchiq U.S. Commercial Launch Underway
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Chikungunya Vaccine Ixchiq Receives ACIP Recommendation
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
2023 Revenue and YE23 Cash Position Announced; 2024 Revenue Guidance Above Consensus But Slightly Below Our Estimate
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
First Participant Dosed in Phase 2 Pediatric Trial for Chikungunya
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Phase 3 VALOR Trial of VLA15 For Lyme Disease Completes Recruitment
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Valneva Reports Positive 24-Month Antibody Persistence Data For Ixchiq
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
EMA Accepts Chikungunya Vaccine MAA for Accelerated Assessment
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Optimized Entry and Exit Levels for VALN 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Valneva SE Sponsored ADR
Industry: Medical - Products
Highlights From Company Call Regarding Chikungunya Vaccine Approval; Adolescent Data Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E